Pfizer wins patent challenge by Mylan |
|
|
|
Published
:
Tue, 27 Feb 2007 22:31
|
PITTSBURGH (AP) - A federal court on Tuesday upheld the validity of a Pfizer Inc. U.S. patent covering the active ingredient in the multi-billion-dollar cardiovascular drug Norvasc, rebuffing a challenge from generic drug maker Mylan Laboratories Inc.Canonsburg, Pa.-based Mylan said it disagrees with the ruling and plans to file an appeal.Judge Terrence F. McVerry of the Western District of Pennsylvania ruled that the patent covering amlodipine besylate is valid and enforceable and that a competing Mylan product would infringe upon it.The decision prohibits Mylan from launching a generic version of amlodipine until September, according to Pfizer.In 2002, Pfizer sued Mylan, alleging that it infringed on Pfizer's patent for Norvasc.The New York-based pharmaceutical company filed the suit two months after Mylan applied to the U.S. Food and Drug Administration for permission to sell a generic version of the drug.Mylan acknowledged infringing on the patent, but claimed the patent was unenforceable. Mylan also contended the patent contained the incorrect formula for the drug and is therefore not valid.The patent trial began in late November.On a day when the Dow Jones Industrial Average suffered its worst decline since Sept. 17, 2001, shares of Pfizer fell 70 cents, or 2.7 percent, to $25.14, while Mylan shares fell 43 cents, or 2 percent, to $21.41, both on the New York stock Exchange.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
Mylan gets FDA nod on generic Zoloft 